Sanofi India shares rise 4% on strong topline and operational show, net profit sharply lower

Sanofi India shares gain above 4% following Q4 earnings announcement

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Sanofi India gained above 4 percent in early trade on February 28 following its Q4FY25 earnings, as the company reported healthy revenue growth even as profitability faced some pressure amid ongoing transformation and expansions.

The shares of Sanofi India are at trading at Rs 5,103 as of 9:45 am, at a gain of 2.33 percent.

For the quarter ended December 2024, the company’s revenue rose by 9.7 percent on-year to Rs 514.9 crore, up from Rs 469.2 crore in the corresponding quarter of the previous year. The topline growth reflects momentum across key therapeutic segments and successful product launches, Sanofi India said. Operational performance improved with EBITDA rising 18.8 percent on-year to Rs 118.3 crore, compared to Rs 99.6 crore in the same period last year. Operating margin expanded to 23 percent from 21.2 percent in the previous year’s fourth quarter, riding on benefits of cost optimization and product mix. Despite healthy operational gains, the net profit declined sharply by 33.7 percent to Rs 91.3 crore, compared to Rs 137.7 crore in the same quarter last year. The contraction in profitability was due to higher expenses in strategic initiatives, product launches, and one-time costs linked to ongoing transformation and expansion.

The board proposed a final dividend of Rs 117 per equity share of Rs 10 face value, subject to approval at the upcoming Annual General Meeting.

Sanofi India’s ongoing transformation is centered around its ‘India for India’ strategy, which emphasizes local innovation, operational efficiency, and enhanced go-to-market capabilities.

One of the major highlights of the year was the successful launch of Soliqua, a diabetes drug targetting the premix segment. The product has seen encouraging early acceptance from healthcare professionals and patients, contributing to the company’s broader diabetes care portfolio.

In addition to diabetes, Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships. Rodolfo Hrosz, Managing Director of Sanofi India said the execution of these partnerships has met expectations, pointing to promising growth potential in coming quarters.